Skip to content

Weissella Cibaria JW15 Consumption and NK Cell Activity

Weissella Cibaria JW15 Consumption and NK Cell Activity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03209635
Enrollment
100
Registered
2017-07-06
Start date
2016-04-01
Completion date
2017-03-20
Last updated
2017-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Function

Brief summary

A The aim of this study was to investigate the impact of consuming Weissella cibaria (W. cibaria) JW15 supplementation isolated from Kimchi, Korea traditional fermented food, on natural killer (NK) cell activity and circulating levels of cytokines and immunoglobulin (Ig).

Detailed description

A randomized, double-blinded, placebo-controlled study was conducted on 100 nondiabetic subjects. Over an eight-week testing period, the probiotic group consumed 4 capsules (300 mg/capsule) containing 1 x 10\^10 colony-forming units (cfu) of W. cibaria JW15 each day, whereas the placebo group consumed the same product without a probiotic.

Interventions

DIETARY_SUPPLEMENTPlacebo

4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product

DIETARY_SUPPLEMENTProbiotic

4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Nondiabetic (fasting serum glucose concentration \< 126 mg/dL) * Subjects with 4,000-8,000 leukocyte counts

Exclusion criteria

* Constant consumption of any probiotic products * Taking medicine related to inflammation within one month before screening * Allergy to probiotics * Lactose intolerance * Diabetes * History/presence of significant metabolic disease * Acute or chronic disease requiring treatment * Taking any medications

Design outcomes

Primary

MeasureTime frameDescription
Natural killer cell activity at baselineBaselineNatural killer cell activity (%)
Natural killer cell activity at 8-week follow up8-week follow upNatural killer cell activity (%)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026